18
Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Israel Gotsman MD The Heart Failure Center, Heart Institute Hadassah University Hospital, Jerusalem, Israel Heart Failure Center Hadassah University Hospital

Type II Pulmonary Hypertension: Pulmonary Hypertension due to

  • Upload
    hamien

  • View
    234

  • Download
    1

Embed Size (px)

Citation preview

Page 1: Type II Pulmonary Hypertension: Pulmonary Hypertension due to

Type II Pulmonary Hypertension: Pulmonary Hypertension due to

Left Heart Disease

Israel Gotsman MD

The Heart Failure Center, Heart Institute

Hadassah University Hospital,

Jerusalem, Israel

Heart Failure Center

Hadassah University Hospital

Page 2: Type II Pulmonary Hypertension: Pulmonary Hypertension due to

• I DO NOT have a financial interest/ arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation.

Page 3: Type II Pulmonary Hypertension: Pulmonary Hypertension due to

Types of Pulmonary Hypertension

Type 1

Type 4

Type 3

Type 2

Page 4: Type II Pulmonary Hypertension: Pulmonary Hypertension due to

World Health Organization (WHO) [Dana Point] Clinical Classification of Pulmonary Hypertension

1. Pulmonary arterial hypertension

2. Pulmonary hypertension due to left heart disease

2.1 Left ventricular systolic dysfunction

2.2 Left ventricular diastolic dysfunction

2.3 Valvular disease 2.4 Congenital/acquired left heart inflow/outflow tract obstruction

and congenital cardiomyopathies

2.5 Congenital/acquired pulmonary veins stenosis

3. Pulmonary hypertension due to lung diseases and/or Hypoxia

4. Chronic thromboembolic pulmonary hypertension

5. Pulmonary hypertension with unclear multifactorial mechanisms

Page 5: Type II Pulmonary Hypertension: Pulmonary Hypertension due to

Pathophysiology

Abnormalities of the left heart:

Elevated left-sided filling pressures

Passive congestion:

Pulmonary venous hypertension

Endothelial dysfunction:

Reactive vasoconstriction

Vascular Remodeling

Long-standing PVH

Long-standing Vasoconstriction

Page 6: Type II Pulmonary Hypertension: Pulmonary Hypertension due to

Mechanism of PHT

Endothelial dysfunction: imbalance between NO and endothelin-1 (ET1) signaling causes abnormalities in smooth muscle tone

Page 7: Type II Pulmonary Hypertension: Pulmonary Hypertension due to

PHT due to LHD - Definition

Mean PAP ≥ 25 mmHg

PCWP > 15 mmHg

+

Isolated post-capillary (Passive)

DPG ≥7 mmHg [TPG>12 mmHg] and/or

PVR >3 WU

DPG <7 mmHg [TPG≤12 mmHg] and/or

PVR ≤3 WU

Combined post & pre-capillary (Reactive)

Reversible with treatment Fixed

DPG = Diastolic pressure gradient (diastolic PAP – mean PAWP) TPG = Transpulmonary pressure gradient (mean PAP – mean PAWP)

Page 8: Type II Pulmonary Hypertension: Pulmonary Hypertension due to

PHT due to Left Heart Disease

• Most common cause of PHT

• Highly prevalent complication of LHD

• Related to disease severity

• Worse symptoms and reduced FC

• Negative impact on outcome

• Clinical Characteristics:

Older, female, higher prevalence of cardiovascular co-morbidities and metabolic syndrome

Page 9: Type II Pulmonary Hypertension: Pulmonary Hypertension due to

PHT in Patients with Heart Failure High prevalence of reactive PHT (>50%)

Schwartzenberg S, J Am Coll Cardiol. 2012

Page 10: Type II Pulmonary Hypertension: Pulmonary Hypertension due to

Prognosis of Pulmonary Hypertension in Patients With Heart Failure

Lam CS, J Am Coll Cardiol. 2009 Abramson SV, Ann Intern Med. 1992

Page 11: Type II Pulmonary Hypertension: Pulmonary Hypertension due to

Prognosis of Pulmonary Hypertension in Patients With Heart Failure

Kjaergaard, Am J Cardiol 2007

Page 12: Type II Pulmonary Hypertension: Pulmonary Hypertension due to

Relation between PAP and RV Function in Patients With Heart Failure

Ghio S, J Am Coll Cardiol. 2001

Page 13: Type II Pulmonary Hypertension: Pulmonary Hypertension due to

Importance of RV Function: Independent and Additive Ominous Prognosis

Ghio S, J Am Coll Cardiol. 2001

High PAP/low RVEF

normal PAP/preserved RVEF

normal PAP/low RVEF high PAP/preserved RVEF

RV failure - Extremely Unfavorable Prognosis

Page 14: Type II Pulmonary Hypertension: Pulmonary Hypertension due to
Page 15: Type II Pulmonary Hypertension: Pulmonary Hypertension due to

Therapy for PHT-LHD

• Treat underlying condition:

• Timely repair of valvular heart disease

• Optimizing therapy and volume status in HFREF

• Control Risk factors for cardiovascular diseases and metabolic syndrome.

• Identify and treat concomitant disorders leading to PHT - COPD, sleep apnea and PE

• Implantation of an LV assist device

Page 16: Type II Pulmonary Hypertension: Pulmonary Hypertension due to

Pharmacological Therapies

Short-term studies demonstrate favorable hemodynamic effects Several trials have shown worsening morbidity or mortality in patients with systolic LHF

Page 17: Type II Pulmonary Hypertension: Pulmonary Hypertension due to

RELAX trial – Negative

Multicenter study - PDE-5 inhibition in HFPEF • No effect on exercise capacity, clinical status, quality of

life, left ventricular remodeling, diastolic function parameters, or pulmonary artery systolic pressure

• Renal function worsened

• NT-proBNP, endothelin-1, and uric acid levels increased

• More withdrew consent, died, or were too ill to perform the cardiopulmonary exercise test

• Higher incidence of vascular adverse events

PDE-5 inhibitor (sildenafil) did not have clinical benefit

Redfield MM, JAMA. 2013

Page 18: Type II Pulmonary Hypertension: Pulmonary Hypertension due to

Therapy for PHT-LHD

Reduce left sided pressures: • Optimized therapy of heart failure

• Timely treatment of valve (Mitral) Disease

• Cardiac resynchronization therapy

• LV Assist Device / transplantation in appropriate patients

Direct therapy – An unmet need